Background: Arterial hypertension is one of the main causes of cardiovascular disease morbidity and overall mortality.
INTRODUCTION
Arterial hypertension is one of the main causes of cardiovascular disease morbidity and overall mortality, including cerebral, cardiac, renal and peripheral vascular diseases. Despite the broad availability of numerous classes of hypotensive medications, half of all hypertensive patients never achieve the recommended levels of blood pressure (BP) [1, 2] . Patient non-compliance with diet, exercise and medical therapy is often cited as a significant contribution to this failure. However, therapeutic inertia and possible adverse events related to lifelong poly pharmacy are also likely. Regardless of the cause of therapeutic failure, hypertensive patients remain at excess risk of renal failure, stroke or myocardial infarction (MI), and it remains a vital healthcare priority to identify alternative and successful treatment options for these patients.
Selectively disabling the renal sympathetic fibres (RD, renal denervation) using a straightforward intra-arterial approach offers significant potential to improve BP management in pharmaceutical-resistant patients, as well as offering a therapeutic option for patients who choose not to be, or cannot be, compliant with a lifelong poly pharmacy strategy for BP control. The concept of sympathetic denervation is not new since radical sympathectomy has been applied in patients with resistant malignant hypertension. However, the new availability of a simple approach and selective renal nerve ablation offer the potential advantages of the surgical approach without the surgical morbidity and complications associated with non-selective sympathetic denervation [3] .
A recently introduced method of percutaneous catheter-based intraluminal selective sympathetic nerve ablation of renal arteries using radiofrequency (RF) current is gaining more attention. Initial studies using this method have shown [4] [5] [6] effective reduction of sympathicomimetic activity and renin secretion as well as an acceptable safety profile and significant reduction in BP levels without major adverse outcomes.
The aim of this study was to assess changes in arterial BP levels in patients after ablation of nerve terminalis in renal arteries (denervation) as well as procedure safety in a six month follow up.
METHODS
The primary enrollment criterion was the presence of resistant arterial hypertension, defined as mean brachial artery seated systolic pressure above 160 mm Hg during out-patient department visits, despite historical compliance with at least three antihypertensive drugs (including a diuretic) in optimal doses. Other enrollment criteria are listed in Table 1 . BP measurement was always performed with an automatic device with a printer -OMRON 7051T, by the same person after ten minutes of rest, three times at five-minute intervals. In order to qualify each patient for the invasive procedure and assess the effect of the procedure, a mean value of three measurements was taken into consideration. Patients with renal failure and renal artery disease or with anatomic contraindications to safe ablation (renal artery lumen diameter < 4 mm, double or narrow renal arteries, critical stenosis) were excluded (see Table 1 for exclusion criteria). Four weeks before the invasive procedure, the mean values of BP in all subjects were stable and pharmacological treatment remained unchanged. No changes in pharmacotherapy were recommended in the follow up period after the procedure.
Twenty-eight patients (median age 52.02 years, range 42-72 years) with diagnosed arterial hypertension resistant to pharmacological treatment were identified and consented to therapeutic RD and the follow up procedures. Baseline characteristics are presented in Table 2 . Height ranged from 147 to 184 cm (mean value 167.8 cm); weight ranged from 60 to 122 kg (mean value 89.5 kg). The co-existing comorbidities included: hypercholesterolaemia was diagnosed in 20 patients, diabetes mellitus type 2 in seven, and peptic ulcer disease in three. Nine patients had prior symptoms of coronary artery disease, of whom one had suffered from MI and had had percutaneous coronary intervention with stent implantation; another had had prior coronary artery bypass surgery. One patient had mild aortic valve stenosis, and one had asthma and chronic obstructive pulmonary disease. Only two patients were diagnosed with chronic renal insufficiency according to elevated creatinine and urea in blood serum. No patient had symptoms of peripheral artery disease. The NYHA scale was 1.8 for this cohort of patients (range 1 to 3). The mean value of three measurements of BP before ablation was: systolic from 160 to 212 mm Hg (mean value 176.6 mm Hg), diastolic from 84 to 121 mm Hg (mean value 100.28 mm Hg). The heart rate ranged from 60 to 98/min (mean value 73.4/min).
The procedure was performed in the usual manner. SIMPLICITY catheters and generators were delivered by the Ardian company (currently Medtronic Inc., USA). All procedures were performed via femoral artery following administration of unfractionated heparin (100 U/kg), a standard for renal artery angiography. There were up to six two-minute pre-programmed applications of RF energy treatments in each renal artery, with a maximum 8 W energy.
The six ablations were performed in a helical pattern, separated by 5 mm. The temperature at the tip of the catheter was monitored by the ablation system as well as tissue resistance to guide therapeutic and safe application of energy by a provided and programmed generator algorithm. After the procedure, patients were followed up in visits at one, three and six months. BP measurements were performed (according to the methodology described earlier), blood count, electrolytes, urea, creatinine and urine were evaluated at each visit, as well as physical exam including orthostatic BP measures.
Patients were monitored for major adverse cardiac events such as death, stroke, MI or outcomes associated with the procedure itself, such as retroperitoneal bleeding, renal artery stenosis, and access site complications. This paper is a subanalysis of the patients recruited to the SIMPLICITY study published in the Lancet in 2009 [4] .
The study was approved by the Bioethics Committee at the Jagiellonian University in Krakow, Poland.
Statistical analysis
For statistical analysis, we assessed continuous variables between groups, including the primary endpoint, with Student's two-sample t test. We compared categorical variables with Fisher's exact test; for within group paired data, a paired t test was used. Two-sided alpha level of 0.05 was used for all superiority testing. All statistical analyses were done with SAS version 9.2.
RESULTS

Periprocedural
There were no access site complications or significant vascular, renal or cardiovascular adverse events reported. During the procedure, many patients reported epigastric diffuse pain predictably starting after each ablation and ending promptly with the end of therapy. Pre procedure sedatives and amnesics were used in all patients and supplemental intravenous opioids were used in most.
All 28 patients were discharged home 2-5 days after the procedure (mean stay was 3.1 days). The hospitalisation length was unrelated to the procedure.
One month after the procedure Twenty-one patients were seen by protocol one month after the procedure. Their weight ranged from 72 to 120 kg (mean value 89.22 kg) and was not statistically different from baseline before the procedure. In this cohort of patients, the mean value of BP was: systolic from 135 to 185 mm Hg (mean value 162.3 mm Hg), and diastolic from 77 to 103 mm Hg (mean value 90.3 mm Hg); this was a mean reduction of 14.3 mm Hg in systolic and 10.02 mm Hg in diastolic BP compared to baseline values. These changes were statistically significant. The mean pulse pressure was 75.18 mm Hg. Of the 21 patients, six (28%) had more than a 10 mm Hg fall in systolic BP (Table 3 , Fig. 1) .
The mean values of heart rate ranged from 60 to 80/min (mean value 72/min) during the one month check-up visit. The mean heart rate was 0.6 bpm lower than the baseline heart rate value, although this was not statistically significant.
No crucial changes in pharmacotherapy or dosages of drugs were noted, nor any complications related to the procedure. One patient reported chest pain in the month following the procedure, but neither non-invasive tests nor subsequent coronary angiography revealed significant coronary artery disease or recent MI. The pain was adjudicated as unrelated to the procedure.
Urine sample tests were within standards. Baseline blood parameters did not reveal a rise in renal parameters used to detect for renal failure. Three months after the procedure Three months after the procedure, 27 patients who had ablation performed were followed up. One patient stopped taking all prescribed medications and was excluded from the three-month analysis. All other patients remained on baseline pharmacotherapy, except for a single patient who had nitrendipine eliminated due to low BP.
The mean value of systolic BP for the remaining 26 patients ranged from 120 to 230 mm Hg (mean value 150.69 mm Hg) and was 26 mm Hg lower than baseline (Table 3 , Fig. 1 ). The mean value of diastolic BP for the remaining 26 patients ranged from 70 to 120 mm Hg (mean value 91.79 mm Hg) and was 8.52 mm Hg lower than baseline.
The mean pulse pressure decreased to 65.86 mm Hg. The mean values of heart rate ranged from 52 to 100/min (mean value 74.39/min) during the three-month check-up visit. The mean heart rate did not differ from baseline and was statistically not significant.
No complications related to the ablation procedure nor adverse events were noted.
Urine sample tests were within standards. Baseline blood parameters did not reveal a rise in renal parameters used to detect for renal failure. The weight ranged from 71 to 105 kg (mean value 90 kg) and was not statistically different from baseline before the procedure.
Six months after the procedure
Six months after the procedure, 26 patients were seen in follow up. All patients remained compliant with baseline pharmacotherapy.
The mean value of systolic BP for the 26 patients ranged from 120 to 190 mm Hg (mean value 147.2 mm Hg) and was 29.4 mm Hg lower than baseline (Table 3 , Fig. 1 ). The mean value of diastolic BP for the 26 patients ranged from 70 to 115 mm Hg (mean value 88.5 mm Hg) and was 11.78 mm Hg lower than baseline before the ablation procedure. The pulse pressure decreased to 62.15 mm Hg (mean value) from baseline 76.57 mm Hg (Table 3) . Systolic, diastolic BP and pulse pressure were statistically significantly lower than at baseline.
The mean values of heart rate ranged from 56 to 104/min (mean value 71.96/min) during the six-month follow up. The mean heart rate was 1.44 bpm lower than that measured before the procedure (statistically not significant).
Urine samples tested six months after the procedure were within standards. Baseline blood parameters did not reveal a rise in renal parameters used to detect for renal failure. The weight six months after the procedure ranged from 60 to 126 kg (mean value 90.3 kg) and was not statistically different from the mean value before the procedure.
DISCUSSION
The results of our study are in line with previously published data [4, 5] , which have shown statistically significant BP reduction after renal artery denervation with RF current in patients with arterial hypertension resistant to pharmacotherapy.
The significant reduction in BP was confirmed during out-patient visits after standardised measurements in pa- Figure 1 . Mean systolic, diastolic blood pressure (BP) and heart rate at baseline and 1, 3 and 6 months after the procedure tients receiving stable antihypertensive pharmacotherapy. In our study, RD led to 29.4 mm Hg decrease in systolic and 11.78 mm Hg decrease in diastolic BP, which was significant compared to baseline value (Fig. 1 ). This reduction of systolic and diastolic BP corresponds to a significant reduction of pulse pressure of 14.42 mm Hg (p < 0.001). No adverse outcomes, complications such as renal failure, or clinically relevant renal artery stenosis occurred during follow up. This Polish report is comparable to the international randomised clinical trial [6] . RD turned out to be a treatment method with sustainable BP decrease in patients with resistant hypertension. After a two-year follow up, observation of 153 patients in whom baseline BP was 176/98 ± 17/15 mm Hg, a mean decrease of 32/14 mm Hg, was achieved which was statistically significant.
Among patients from the Simplicity I and Simplicity II trials assessed together, 84% of patients had durable lowering of BP (mean decrease in systolic BP was 32 mm Hg, and for the diastolic BP 12 mm Hg after six months; p < 0.001) [7] .
There is a cardiovascular mortality and cardiovascular morbidity benefit from a successful BP lowering therapy (systolic, diastolic and pulse pressure) [8] [9] [10] [11] [12] . The effect on all-cause mortality is less pronounced, while the reduction of mortality is principally related to a reduction of cerebrovascular events. Meta analysis supports a 2% reduction of mortality for every 1 mm Hg reduction of systolic BP. The obvious BP lowering, especially the pulse pressure, certainly reflects future risk benefit for these patients, however, it is as yet too early to estimate the overall outcome of adverse events such as death, stroke and MI in long term observation in this smaller series. Nonetheless, the patients enrolled had exhausted alternative therapy, and RD has provided a calculable benefit in this cohort.
None of the current reports identify serious adverse events of the procedure, while several note transient bradycardia pseudoaneurysms in access site, rapid onset hypotonia, urinary tract infections, parestesia and pain, all self limited complications. Out of 206 patients who had denervation performed in the analysis of published studies, only five had complications in the form of pseudoaneurysms and dissection of renal artery caused by the ablation catheter [12] .
To date, no long term vascular or renal complications have been identified [13] . The ablation itself is sterile, and preclinical trials show healed non-inflammatory lesions with mature fibrosis at the ablation sites, suggesting that there is little risk of late vascular complications. There is a theoretical potential for efferent sympathetic fibres to regrow, but it is generally felt that afferent fibres cannot. The recent report of sustained BP reduction out to three years (ACC 2012) confirms the durability of the procedure [14] .
The benefits of RD may not be confined to the reduction of BP. Metabolic effect in hypertensive patients and associated with improvement of glucose tolerance and sleep apnoea was confirmed by Witkowski et al. [15] and in a study of RD in patients with polycystic ovary syndrome [16] . The improvement on glucose tolerance was not associated with current therapy with insulin or oral drugs which has also been confirmed in other studies [17] . In our study, however, no observation focused on glucose tolerance was undertaken.
The potential of RD for patients who are persistently non-compliant, or who have proved intolerant to medications, has not been explored and the value of the therapy in patients with secondary hypertension, such as aldosteronism, remains to be investigated. Also, the value of this therapy in earlier non-resistant hypertension remains unexplored.
The role of sympathetic efferent and afferent somatic fibres in hypertension has long been proved in animal models, where efferent signals increase renin release, cause a rightward shift of the pressure natriuresis curve, and reduce renal bloodflow. Interfering with the deleterious effects of these signals may explain much of the underlying mechanism of BP reduction seen in this trial. Moreover, the potential of the kidney to modify the central sympathetic state via signals from its resident afferent somatic chemo and mechanoreceptors is intriguing. The reduction of total body noradrenaline and muscle sympathetic nerve activity supports this novel hypothesis [4, 6, 18] .
If true, then the selective reduction of renal signalling to the hypothalamus may have value in the treatment of other disorders related to sympathetic hyperactivity, such as heart failure with preserved or reduced ejection fraction, hypertrophic heart disease, and ventricular hypertrophy, tachyarrhythmias, post myocardial ventricular dilation, insulin resistance, advancing chronic renal disease, and polycystic ovary syndrome.
CONCLUSIONS
Denervation (ablation) of sympathetic fibres in renal arteries was a safe procedure in this cohort of patients. Selective renal nerve ablation with RF energy via the renal artery using the Ardian system (Medtronic) led to significant and sustained decreases in mean values of arterial systolic and diastolic BP and pulse pressure in a six month follow up in patients with resistant hypertension with optimal pharmacotherapy compared to baseline measurements. In the absence of successful pharmacotherapy in this population, the procedure now adds benefit to their care. Certainly long term vascular and renal safety data will be required. The application of this therapy to patients whose BP has not proved resistant to life-long polypharmacy, or additional disease states such as heart failure, insulin resistance or type 2 diabetes, post myocardial ventricular dilation, tachycardia arrhythmias such as atrial fibrillation, and polycystic ovary syndrome, will require further investigation. 
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